A carregar...
The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia
There are currently no regulatory approved pharmacological treatments for cognitive impairment associated with schizophrenia (CIAS). One possibility is that trial methodology itself is hindering their development. Emerging evidence suggests that patients with schizophrenia may show limited benefit f...
Na minha lista:
| Publicado no: | Front Psychiatry |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6743013/ https://ncbi.nlm.nih.gov/pubmed/31551837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpsyt.2019.00648 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|